Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 305 participants.

Also called NCT05593575

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 305 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05593575
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05593575. Randomized; double masking; primary purpose treatment. Start 2023-03-22 (actual); primary completion 2024-12-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease
Condition
Diabetic Kidney Disease
Intervention (Drug)
SPH3127+SPH3127matching placebo+valsartan matching placebo
Intervention (Drug)
SPH3127+SPH3127matching placebo+valsartan matching placebo
Intervention (Drug)
SPH3127+valsartan matching placebo
Intervention (Drug)
SPH3127 matching placebo+valsartan
Lead sponsor
Shanghai Pharmaceuticals Holding Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct05593575
Content hash
69d516062a0782ee142435d9a18ddcd8406f1e8f6fe89677df24a30c6be0ed40